ARCA Biopharma Inc

About ARCA Biopharma Inc

ARCA Biopharma (NASDAQ: ABIO) focuses on developing genetically-targeted therapies for cardiovascular diseases. They're working on innovative projects like Gencaro, aimed at treating atrial fibrillation in heart failure patients. Their objective is to harness precision medicine to improve patient outcomes, leveraging genetic insights to create more effective treatments. With a clear dedication to advancing cardiovascular health, ARCA is pushing the boundaries of biopharmaceutical innovation.

What is ARCA Biopharma Inc known for?

Snapshot

2004

Year founded

Employees

Westminster, United States

Head office

Loading Map...

Operations

All Locations

Westminster, US

Products and/or services of ARCA Biopharma Inc

Gencaro: A precision medicine program for developing targeted therapies to treat cardiovascular diseases, specifically heart failure and atrial fibrillation.
Nuventra: Strategic partnership for clinical pharmacology and pharmacokinetic expertise to accelerate drug development.
Ethics-First Approach: Prioritizing patient safety and rigorous ethical standards in all research and development initiatives.
Adaptive Clinical Trial Design: Utilizing advanced clinical trial methodologies to optimize drug development processes and outcomes.
Biomarker Development: Identifying and validating biomarkers to enhance the precision and efficacy of treatment modalities.
Regulatory Expertise: Leveraging in-depth knowledge of regulatory pathways to expedite the approval and commercialization of innovative therapies.